BC Innovations | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

Preclinical studies showing the utility of CAR T cells outside of cancer are ramping up, and developers have taken notice. But turning the modality into a general-purpose tool will require companies to break through safety...
BC Week In Review | Sep 21, 2018
Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

Cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, Cowen and Jefferies. Launched in April with...
BC Extra | Sep 14, 2018
Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

Cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, Cowen and Jefferies. Launched in April with...
Items per page:
1 - 3 of 3